Introduction: In the randomized KEYNOTE-407 study (ClinicalTrials.gov, NCT02775435), pembrolizumab plus carboplatin and paclitaxel/nab-paclitaxel (chemotherapy) significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo plus chemotherapy in patients with previously untreated metastatic squamous NSCLC. We report updated efficacy outcomes from the protocol-specified final analysis and, for the first time, progression on next line of treatment.
Methods: Eligible patients were randomized to chemotherapy plus either pembrolizumab (n = 278) or placebo (n = 281). After positive results from the second interim analysis, patients still receiving placebo could cross over to pembrolizumab monotherapy at the time of confirmed progressive disease. The primary end points were OS and PFS. PFS-2 (time from randomization to progression on next-line treatment/death, whichever occurred first) was an exploratory end point.
Find out the temperature of sea water in more than 12000 cities and resorts around the world. Water surface temperature values are available in real time. There is a forecast of water temperature changes for the next few days, as well as historical data of sea surface temperature are available for all days of the last years.
Great insurance! Bought one year but was cured in 2 days on my visit to El Sauzal de Rodriguez next to Ensenada.Not an enjoyable place to... visit. You can't even go in the ocean. Baja bound refunded the remaining and I'm highly satisfied!
Armin Hamidovic was sitting on a bed next to two women in a room at a Red Roof Inn on February 26. The Star, citing court records, reported that one of the women was the ex-girlfriend of 18-year-old Isaac Perdomo-Paz. 781b155fdc